Your browser doesn't support javascript.
loading
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
Carter, Cristina; Houser, Katherine V; Yamshchikov, Galina V; Bellamy, Abbie R; May, Jeanine; Enama, Mary E; Sarwar, Uzma; Larkin, Brenda; Bailer, Robert T; Koup, Richard; Chen, Grace L; Patel, Shital M; Winokur, Patricia; Belshe, Robert; Dekker, Cornelia L; Graham, Barney S; Ledgerwood, Julie E.
Afiliação
  • Carter C; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Houser KV; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Yamshchikov GV; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Bellamy AR; The Emmes Corporation, Rockville, MD, United States of America.
  • May J; The Emmes Corporation, Rockville, MD, United States of America.
  • Enama ME; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Sarwar U; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Larkin B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Bailer RT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Koup R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Chen GL; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Patel SM; Departments of Medicine and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States of America.
  • Winokur P; Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, United States of America.
  • Belshe R; Division of Infectious Diseases, Allergy and Immunology, Saint Louis University, St. Louis, MO, United States of America.
  • Dekker CL; Department of Pediatrics (Infectious Diseases), Stanford University Medical Center, Stanford, CA, United States of America.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
  • Ledgerwood JE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
PLoS One ; 14(9): e0222178, 2019.
Article em En | MEDLINE | ID: mdl-31532789

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Vacinas de DNA / Influenza Humana / Hemaglutininas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Vacinas de DNA / Influenza Humana / Hemaglutininas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos